DMT210 Topical Gel in the Treatment of Atopic Dermatitis

Completed · Phase 2

Conditions studied: Atopic Dermatitis

In brief

The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild to moderate atopic dermatitis (AD).

Key facts

Study ID

NCT02949960

Run by

Dermata Therapeutics

People needed

19

Starts

2016-10-01

Expected to finish

2017-07-14

Last updated by the study team

2018-04-18

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female 12 years or older
• Patient has chronic, stable AD that has been present for at least 3 months with 5-35% (inclusive) BSA (Body Surface Area) of AD involvement
• Patient has two analogous, Target Lesions; one lesion within each of the two Treatment Areas
• Patient is willing and able to comply with the protocol

You may not qualify if…

• Patient has used topical therapies for AD within the Treatment Areas 2 weeks before baseline

Where it is running

• Dermata Investigational Site — Houston, Texas, United States
• Dermata Investigational Site — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.